Literature DB >> 2119884

Gamma-interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells.

C Marth1, E Müller-Holzner, E Greiter, M V Cronauer, A G Zeimet, W Doppler, B Eibl, N E Hynes, G Daxenbichler.   

Abstract

The overexpression of the protooncogene c-erbB-2 (HER-2/neu) in ovarian and mammary carcinoma is an important indicator for a bad prognosis. In this study we demonstrate that, in three of four ovarian carcinoma cell lines, there is a gamma-interferon-mediated reduction in c-erbB-2 specific protein, and this effect was found to correlate with the antiproliferative action. It is interesting to note that there is no relation between the absolute amount of c-erbB-2 protein expressed and the sensitivity of the ovarian carcinoma cells for an antiproliferative activity of gamma-interferon. Other chemotherapeutic agents did not affect c-erbB-2 expression, although they inhibited the proliferation. The oncogene expression was lowered only in the ovarian carcinoma cell lines and not in three gamma-interferon-sensitive human breast cancer cell lines. Expression of the oncogene c-erbB-2 is the leading prognostic factor in ovarian cancer. Its modulation might represent a mechanism by which gamma-interferon inhibits cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2119884

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  Immunotherapy for ovarian cancer.

Authors:  Justin M Drerup; Yang Liu; Alvaro S Padron; Kruthi Murthy; Vincent Hurez; Bin Zhang; Tyler J Curiel
Journal:  Curr Treat Options Oncol       Date:  2015-01

2.  Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model.

Authors:  Nafiseh Pakravan; Zuhair Mohammad Hassan
Journal:  Cell Stress Chaperones       Date:  2011-02-26       Impact factor: 3.667

3.  HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses.

Authors:  Maciej Kmieciak; Keith L Knutson; Catherine I Dumur; Masoud H Manjili
Journal:  Eur J Immunol       Date:  2007-03       Impact factor: 5.532

Review 4.  The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis.

Authors:  Katie Lin; Stavroula Baritaki; Silvia Vivarelli; Luca Falzone; Aurora Scalisi; Massimo Libra; Benjamin Bonavida
Journal:  Antioxidants (Basel)       Date:  2022-06-17

5.  Analysis of c-erbB2 protein content of human glioma cells and tumor tissue.

Authors:  H H Engelhard; M Wolters; P S Criswell
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

6.  Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor alpha.

Authors:  H Kalthoff; C Roeder; J Gieseking; I Humburg; W Schmiegel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

7.  Changes in CA125 release and surface expression caused by drugs in uterine cervix adenocarcinoma cells.

Authors:  T Nakai; H Sakahara; K Endo; M Shirato; H Kobayashi; M Hosono; T Saga; M Sakamoto; J Konishi
Journal:  Ann Nucl Med       Date:  1993-08       Impact factor: 2.668

8.  Disabling of the erbB Pathway Followed by IFN-γ Modifies Phenotype and Enhances Genotoxic Eradication of Breast Tumors.

Authors:  Yasuhiro Nagai; Hiromichi Tsuchiya; E Aaron Runkle; Peter D Young; Mei Q Ji; Larry Norton; Jeffrey A Drebin; Hongtao Zhang; Mark I Greene
Journal:  Cell Rep       Date:  2015-09-10       Impact factor: 9.423

9.  Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells.

Authors:  C Marth; M Widschwendter; J Kaern; N P Jørgensen; G Windbichler; A G Zeimet; C Tropé; G Daxenbichler
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth.

Authors:  I M Harwerth; W Wels; J Schlegel; M Müller; N E Hynes
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.